Scancell Holdings Plc SCLP

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) told investors it has secured up to US$25 million of debt financing from funds and accounts managed by BlackRock, bolstering the funding package for the registrational Phase 3 trial of its lead melanoma treatment iSCIB1+. The company plans...

OXFORD, United Kingdom and BURLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP) (“Scancell”, or the “Company”), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announced today that, further to its announcement on 23 July 2026 regarding the planned merger with Neuphoria Therapeutics Inc. (“Neuphoria”) and financing to conduct the registrational Phase 3

A landmark trial success for Moderna and Merck's cancer vaccine has strengthened the case for Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the immuno-oncology company developing a rival melanoma treatment, according to one broker covering the sector's innovative small-caps. Merck and...

A rally in government bonds eases pressure on equities

Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF) has upgraded its Pitfield project in Western Australia to 8.16 billion tonnes, confirming it as the world's largest titanium resource. That includes a first Measured Resource of 374 million tonnes at a solid 5.8% grade. Vast Resources PLC (LSE:VAST, FRA:D9A) has completed its takeover of Gulf International Minerals, adding a producing gold and silver mine in Tajikistan. It's also raised around £7.5 million to fund the next stage of development following its re-admission to London's AIM. Rockfire Resources PLC (LSE:ROCK) has hit fresh high-grade zinc and

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the cancer immunotherapy developer, has won UK regulatory approval to run a late-stage trial of its lead drug in advanced melanoma. The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a clinical trial authorisation...

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) confirmed the UK leg of its equity funding has raised gross proceeds of £15.7 million after strong retail demand prompted the cancer immunotherapy developer to increase the size of its retail offer. The retail offer raised £2.7...

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) saw its shares drop 27% this week, but the movement obscures the real story, which is a largely positive one for investors. It may take the market a while to process some transformational changes that will see the oncology research...

Neuphoria Therapeutics (NEUP) and Scancell Holdings said Thursday they have agreed to an all-stock m

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the Oxford-based cancer immunotherapy developer listed on London's junior AIM market, has agreed an all-share merger with US biotech Neuphoria Therapeutics that will give it a Nasdaq listing and access to American investors. The combined...

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to an announcement made by London-listed biotechnology compan

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the developer of immunotherapies designed to treat cancer, has confirmed it is in advanced discussions over a reverse merger with US-listed Neuphoria Therapeutics. Responding to press speculation, the AIM-quoted company confirmed it is...

EnergyPathways PLC (AIM:EPP) has launched Front End Engineering and Design for what could become the world's largest compressed air energy storage project. Pre-FEED work with Siemens Energy confirmed the project's viability, with a £15 million financing package now in place to fund the next phase. Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) has secured FDA Fast Track Designation for its lead cancer drug iSCIB1+ in advanced melanoma. Phase II trial data shows 77% progression-free survival at 20 months, compared with 43% for the current standard of care. Poolbeg Pharma PLC (AIM:POLB, OT

Panmure Liberum holds its 'buy' rating and 32p target as FDA fast-track status adds regulatory momentum to compelling trial data. Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) shares rose 5.3% to 13.69p on Tuesday as the cancer immunotherapy developer delivered a double dose of...

Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and additional early overall survival (OS) data expected in H1 2027 Initiation of the registrational Phase 3 trial with iSCIB1+ in advanced melanoma anticipated in H2 2026 OXFORD, United Kingdom, April 28, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to t

Trump warned the US would step up strikes on Iran over the next two to three weeks

Sorted Group Holdings (AIM:SORT) saw its share price halve to 10p after announcing plans to sell its main business for just £1. The company will become an AIM cash shell and has six months to make an acquisition or face suspension. Cancer immunotherapy developer Scancell Holdings (AIM:SCLP, OTC:SCNLF, FRA:SCP) has named David Schilansky as interim CFO as its current finance chief prepares to leave. Schilansky has previously raised more than $1 billion for listings on Nasdaq and Euronext, experience that could prove useful as Scancell explores a US listing. Active Energy Group (AIM:AEG, OTCID:A

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), th cancer immunotherapy developer, has named David Schilansky as financial adviser and interim chief financial officer as current CFO Sath Nirmalananthan prepares to leave the company. Nirmalananthan will step down from the board on 24...